In patients with adrenal insufficiency receiving dexamethasone replacement, the guideline suggests increasing the dexamethasone dose when enzyme-inducing antiepileptic drugs are co-administered. Trigger phrases include "AI patient on dexamethasone starts enzyme-inducing antiepileptic drug" or "AI patient on dexamethasone requiring enzyme-inducing AED".
Installs into .claude/skills of the current project.
Are you the author of Ata Dexamethasone Aed Adjustment?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-ata-dexamethasone-aed-adjustment)
---
name: ata-dexamethasone-aed-adjustment
description: In patients with adrenal insufficiency receiving dexamethasone replacement, the guideline suggests increasing the dexamethasone dose when enzyme-inducing antiepileptic drugs are co-administered. Trigger phrases include "AI patient on dexamethasone starts enzyme-inducing antiepileptic drug" or "AI patient on dexamethasone requiring enzyme-inducing AED".
---
# Increase dexamethasone dose when enzyme-induced antiepileptic drugs are co-administered
## STEP 1 — Gather Information
Confirm adrenal insufficiency diagnosis, current dexamethasone dose and schedule, and whether the patient is prescribed or taking an enzyme-inducing antiepileptic drug (e.g., phenytoin, carbamazepine, oxcarbazepine, phenobarbital, primidone).
## STEP 2 — Rule In / Rule Out
Determine if the antiepileptic drug is enzyme‑inducing (induces CYP3A4). If yes, proceed to dose adjustment; if the AED is non‑enzyme‑inducing (e.g., levetiracetam, lamotrigine, gabapentin), no dexamethasone dose change is needed.
## STEP 3 — Classify or Stratify
Assess for clinical signs of adrenal insufficiency (fatigue, hypotension, hyponatremia, hyperkalemia) and note the baseline dexamethasone dose to guide the magnitude of increase.
## STEP 4 — Decide
Increase dexamethasone dose empirically (e.g., by 25–50%) and monitor for symptom resolution and signs of glucocorticoid excess; adjust further based on clinical response.
## Clinical Guardrails / Mimics / Pitfalls
Do not increase dose for non‑enzyme‑inducing AEDs; avoid abrupt changes that may cause iatrogenic Cushingoid features; monitor for symptoms of glucocorticoid excess; interpret morning cortisol cautiously due to assay variability and CBG effects; ensure patient education on stress dosing and emergency hydrocortisone.
## Concrete Clinical Example
A 50‑year‑old man with secondary AI on dexamethasone 0.25 mg nightly begins carbamazepine 400 mg BID for trigeminal neuralgia; after 10 days he develops worsening fatigue and orthostatic hypotension; dexamethasone is increased to 0.35 mg nightly; symptoms improve within one week.
**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118
